Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04209790 · ClinicalTrials.gov registry record · Phase 2
Neoadjuvant Chemoradiation for Resectable Glioblastoma
A Phase 2 study, sponsored by Geisinger Clinic.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT04209790 is a Phase 2 study that was terminated before completion, run by Geisinger Clinic. The registered enrollment target is 2 participants.
The verdict
NCT04209790, a Phase 2 study, was terminated before completion, sponsored by Geisinger Clinic.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
Preoperative therapy has not been well studied in resectable glioblastoma. This study attempts to prospectively assess the feasibility and efficacy of preoperative chemo radiation in improving local control, as this is the predominant mode of failure in these patients leading to poor outcomes. This Phase II study design would be used to proceed with the study treatment after meeting pre-specified events in the initial phase, with goal being to determine whether the new treatment paradigm is sufficiently promising to warrant a major controlled clinical evaluation against the standard therapy.
Interventions
- RADIATION Neoadjuvant chemoradiation
- DRUG Drug Therapy with Temozolomide (benzolamide) (Standard of Care)
- PROCEDURE Surgery post Radiation and Temozolomide (benzolamide)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2020-04-01 |
| Est. Completion | 2022-09-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04209790
The ClinicalTrials.gov registry entry for NCT04209790 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Geisinger Clinic, which has 107 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Neoadjuvant chemoradiation is the first listed.
NCT04209790 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04209790 about?
NCT04209790 is a clinical study titled "Neoadjuvant Chemoradiation for Resectable Glioblastoma". Preoperative therapy has not been well studied in resectable glioblastoma. This study attempts to prospectively assess the feasibility and efficacy of preoperative chemo radiation in improving local control, as this is the predominant mode of failure in these patients leading to poor outcomes. This...
What is the current status of trial NCT04209790?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2020-04-01. Estimated completion is 2022-09-14.
What interventions are being tested in trial NCT04209790?
The interventions under investigation include: Neoadjuvant chemoradiation (RADIATION), Drug Therapy with Temozolomide (benzolamide) (Standard of Care) (DRUG), Surgery post Radiation and Temozolomide (benzolamide) (PROCEDURE).
Who is sponsoring clinical trial NCT04209790?
This trial is sponsored by Geisinger Clinic, which has 107 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.